# Eylea HD Approved for RVO and Extended Dosing

Page: https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/eylea-hd-approved-for-rvo-and-extended-dosing
Text version: https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/eylea-hd-approved-for-rvo-and-extended-dosing.md
Podcast: [Eyewire News: The Podcast](https://stenobird.com/podcast/eyewire-news-the-podcast-7055536)
Published: 2025-12-03T20:39:00+00:00
Episode link: https://traffic.megaphone.fm/BMCL2530398360.mp3
Audio file: https://traffic.megaphone.fm/BMCL2530398360.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/eylea-hd-approved-for-rvo-and-extended-dosing
Duration seconds: 300

## Resource

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/eylea-hd-approved-for-rvo-and-extended-dosing/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/eylea-hd-approved-for-rvo-and-extended-dosing.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.